SEC Eyes Dendreon, Possibly Over Provenge Launch

Law360, New York (May 16, 2012, 10:06 PM EDT) -- Dendreon Corp. has recently become the subject of a U.S. Securities and Exchange Commission investigation that the biotechnology company believes could be related to various class actions over the release of its prostate cancer drug Provenge.

Dendreon disclosed the existence of the investigation in a May 7 regulatory filing. No further details of the investigation were revealed and a representative for the company could not immediately be reached for comment Wednesday.

The company and its current and former officers are battling a putative class action in...
To view the full article, register now.